Disclosures for "A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD)")
-
Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received research support from Sarepta.
-
Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PTC. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Grifols. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Shieh has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avexis.
-
Dr. Sahenk has nothing to disclose.
-
Ms. Lehman has nothing to disclose.
-
The institution of Ms. Lowes has received research support from Sarepta Therapeutics.
-
Dr. Reash has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ATOM International. Dr. Reash has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Casimir, LLC. The institution of Dr. Reash has received research support from Sarepta. Dr. Reash has received intellectual property interests from a discovery or technology relating to health care. Dr. Reash has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Iammarino has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech.
-
Ms. Alfano has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ATOM International, Ltd (Amicus Therapeutics, Catabasis, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics). Ms. Alfano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Novartis Gene Therapies. The institution of Ms. Alfano has received research support from Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Audentes Therapeutics/Astellas Gene Therapies. Ms. Alfano has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Sabo has nothing to disclose.
-
Jeremy Woods has nothing to disclose.
-
Christy Skura has nothing to disclose.
-
Howard Mao has nothing to disclose.
-
Loretta Staudt has nothing to disclose.
-
Rachael Potter has received stock or an ownership interest from Sarepta Therapeutics.
-
Ms. Griffin has stock in Sarepta Therapeutics. Ms. Griffin has received intellectual property interests from a discovery or technology relating to health care.
-
Sarah Lewis has received stock or an ownership interest from Sarepta.
-
Shufang Wang has received personal compensation for serving as an employee of Sarepta Therapeutics INC. Shufang Wang has received stock or an ownership interest from Sarepta Therapeutics INC.
-
Tejdip Singh has received personal compensation for serving as an employee of Sarepta Therapeutics . Tejdip Singh has received stock or an ownership interest from Sarepta Therapeutics.
-
Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care.